LPV/r 200+50mg heat/st tabs/PAC-120

NOTE: The description below is for a standard product. It is not specific to patent status and pricing policies that may apply at country level. This information is available on request from Supply Division: Contact: supply@unicef.org

General Description:
Lopinavir 200mg + Ritonavir 50mg film coated heat stable tablets, pack of 120

Technical Specifications:
Each film coated tablet contains a fixed boosted protease inhibitor combination of Lopinavir 200mg + Ritonavir 50mg in a heat stable formulation

Therapeutic class:
Protease Inhibitors (PI)

Standard shelf life:
2 years (24 months)

Other available formulations:
The product may also be available in other formulations, pack sizes, or in combinations with other ARVs.

Guidelines for use:
For more details, please click the links listed below:

WHO treatment guidelines


and

WHO Essential Medicines Library


or your regional national guidelines

For details about paediatric dosage schemes, please click the links listed below:

WHO HIV/AIDS


WHO Generic tool for assessing paediatric ARV dosing



Indications:
Management of HIV-1 infection in infected adults and children above 2 years of age in combination with at least two other antiretroviral drugs; by mouth (PO)

NOTE:
Ritonavir increases effect of Lopinavir; it is used in this co-formulation as a booster to Lopinavir and this low dose in combination does not have intrinsic antiviral activity

Storage:
Do not store above 30ºC (86°F)
Store in tightly closed original container
Keep out of reach and sight of children

Dispensing instructions:
Dispense in original container; do not re-pack
Tablet should not be broken or crushed. Should be swallowed whole

Regulatory status:
For latest updates, please click the links listed below:

List of WHO Prequalified Medicines


List of USFDA approved and tentatively approved items

Important information regarding supply for this product

Please click on the link:
http://www.unicef.org/supply/index_81996.html